Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

In trading on Tuesday, shares of Johnson & Johnson (Symbol: JNJ) crossed above their 200 day moving average of $156.46, changing hands as high as $157.44 per share. Johnson & Johnson shares are ...

Johnson & Johnson shows strong profitability and solid value, but faces growth uncertainty, legal risks, and pricing pressures. Read why JNJ stock is a buy.

Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong phase III data.

Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 1 study results for Pasritamig, a novel antibody for advanced prostate cancer, which may have influenced its stock's 1.5% rise last ...

Johnson & Johnson JNJ shared data from several cancer studies at the 2025 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday. Here’s that the New Brunswick, New Jersey-based ...

Johnson & Johnson (NYSE:JNJ) is one of the best stocks for a retirement stock portfolio. On June 12, UBS global equity strategist Andrew Garthwaite’s team pointed to Johnson & Johnson as one of ...

Johnson & Johnson said the first clinical data from its ongoing Phase 1b study of JNJ-4496, a chimeric antigen receptor T-cell therapy, shows encouraging potential in treating large B-cell ...

When Elon Musk came out against President Donald Trump’s massive tax and spending bill, Sen. Ron Johnson saw it as something of a vindication.

Several years ago I bought shares of 3M (NYSE: MMM) even though it was in the middle of a major class-action lawsuit. Here's why you also might want to skip J&J and buy Medtronic (NYSE: MDT) instead.